The two main causes of death in cancer patients are metastasis and resistance to therapy. The Signalling in Cancer Unit seeks to understand both the molecular mechanisms involved in the formation of secondary tumours (metastasis) and the strategies used by cancer cells to resist chemotherapy drugs and targeted therapies.
The ultimate goal of the Unit is to transfer results to clinical practice.
- Anoikis resistance as a metastasis prevention strategy in melanoma-type skin cancer.
- New treatments for glioblastoma multiforme.
- Personalised medicine for neuroendocrine tumours.
- Metabolic adaptation and tumour progression in melanoma.
Navarrabiomed - Centro de investigación biomédica
Complejo Hospitalario de Navarra, edificio de investigación.
Calle Irunlarrea, 3. 31008 Pamplona, Navarra, España.